A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3) in HIV Infected Patients With Cytopenia

Inclusion Criteria Patients must have: * HIV seropositivity by Western blot. * Advanced ARC or AIDS as defined by CDC. * Cytopenia defined as total peripheral leukocyte count of \< 3,000 cells/mm3 or platelet count of \< 100,000 cells/mm3 or serum hemoglobin \< 10 g/dl. * Anticipated life expectancy = or \> 6 months. * Ambulatory. * Willing to sign informed consent. * Willing to forego use of any other investigational therapies except ddI. Prior Medication: Allowed \> 2 weeks prior to study entry: * zidovudine. * Allowed \> 4 weeks prior to study entry: * systemic cytotoxic chemotherapy; investigational drugs; medications known to be myelosuppressive as ganciclovir, trimethoprim/sulfamethoxazole or dapsone. * Allowed \> 6 weeks prior to study entry: * other hemopoietic growth factor treatment as GM-CSF, EPO. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: * Active opportunistic infection. * Symptoms of CNS disease referable to HIV infection. * Dementia or altered mental status that would prohibit giving and understanding informed consent. Systemic chemotherapy. * Investigational therapies other than ddI. * Medications with known myelosuppressive effects such as ganciclovir, trimethoprim/sulfamethoxazole or dapsone or AZT. * Other hematopoietic growth factor treatments as GM-CSF, G-CSF, or EPO. Prophylactic therapy for pneumocystis or oral thrush. * ddI. * Corticosteroids or topical corticosteroid creams. Patients may not have: * Life expectancy \< 6 months. * Active drug or alcohol abuse. * Active opportunistic infections. * Treatment with any other investigational drugs except ddI within 4 weeks of study entry. * Dementia or altered mental state that prohibits giving informed consent. * Symptoms of CNS disease referable to HIV infection. * Major surgery within 4 weeks of study entry. * History of major pulmonary or cardiac disease. * History of any prior malignancy other than Kaposi's sarcoma or noninvasive subcutaneous carcinoma. * Documented allergic disorder such as asthma, history of anaphylaxis, atopy, serum sickness, or bronchospasm. Not allowed within 2 weeks prior to study entry: * zidovudine (AZT). * Not allowed within 4 weeks prior to study entry: * systemic cytotoxic chemotherapy; investigational drugs other than ddI; medications known to be myelosuppressive as ganciclovir, trimethoprim/sulfamethoxazole or dapsone. * Not allowed within 6 weeks prior to study entry: * other hematopoietic growth factor treatment as GM-CSC, G-CSF, EPO. Radiation therapy or major surgery within 4 weeks of study entry. Active drug or alcohol abuse.